Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glucose-6-phosphatase (Glc6Pase), the last enzyme of gluconeogenesis, is only expressed in the liver, kidney and small intestine. The expression of the Glc6Pase gene exhibits marked specificities in the three tissues in various situations, but the molecular basis of the tissue specificity is not known. The presence of a consensus binding site of CDX proteins in the minimal Glc6Pase gene promoter has led us to consider the hypothesis that these intestine-specific CDX factors could be involved in the Glc6Pase-specific expression in the small intestine. We first show that the Glc6Pase promoter is active in both hepatic HepG2 and intestinal CaCo2 cells. Using gel shift mobility assay, mutagenesis and competition experiments, we show that both
CDX1
and CDX2 can bind the minimal promoter, but only
CDX1
can transactivate it. Consistently, intestinal IEC6 cells stably overexpressing
CDX1
exhibit induced expression of the Glc6Pase protein. We demonstrate that a TATAAAA sequence, located in position -31/-25 relating to the transcription start site, exhibits separable functions in the preinitiation of transcription and the transactivation by
CDX1
. Disruption of this site dramatically suppresses both basal transcription and the
CDX1
effect. The latter may be restored by inserting a couple of CDX- binding sites in opposite orientation similar to that found in the sucrase-isomaltase promoter. We also report that the specific stimulatory effect of
CDX1
on the Glc6Pase TATA-box, compared to CDX2, is related to the fact that
CDX1
, but not CDX2, can interact with the
TATA-binding protein
. Together, these data strongly suggest that CDX proteins could play a crucial role in the specific expression of the Glc6Pase gene in the small intestine. They also suggest that CDX transactivation might be essential for intestine gene expression, irrespective of the presence of a functional TATA box.
...
PMID:Differential regulation of the glucose-6-phosphatase TATA box by intestine-specific homeodomain proteins CDX1 and CDX2. 1295 59
We have previously reported that the
CDX1
homeoprotein interacts with the
TATA-box binding protein
(
TBP
) on the promoter of the glucose-6-phosphatase (G6Pase) gene. We show here that
CDX1
interacts with
TBP
via the homeodomain and that the transcriptional activity additionally requires the N-terminal domain upstream of the homeodomain.
CDX1
interacting with
TBP
is connected to members of the TFIID and Mediator complexes, two major elements of the general transcriptional machinery. Transcription luciferase assays performed using an altered-specificity mutant of
TBP
provide evidence for the functionality of the interaction between
CDX1
and
TBP
. Unlike
CDX1
, CDX2 does not interact with
TBP
nor does it transactivate the G6Pase promoter. Swapping experiments between the domains of
CDX1
and CDX2 indicate that, despite opposite functional effects of the homeoproteins on the G6Pase promoter, the N-terminal domains and homeodomains of both
CDX1
and CDX2 have the intrinsic ability to activate transcription and to interact with
TBP
. However, the carboxy domains define the specificity of
CDX1
and CDX2. Thus, intra-molecular interactions control the activity and partner recruitment of
CDX1
and CDX2, leading to different molecular functions.
...
PMID:Functional interaction between the homeoprotein CDX1 and the transcriptional machinery containing the TATA-binding protein. 1715 64